Pharmaceutical care to patients with viral hepatitis type C treated at distrito federal- Brazil
- At: 2010 FIP Congress in Lisbon (Portugal)
- Type: Poster
- By: BITAR, Rachel (Secretaria de Saúde do GDF, Brasilia, Brazil)
- Co-author(s): Vidotti, Carlos (Universidade Católica de Brasília, Brasilia, Brazil)
BACKGROUND: Infection hepatitis C virus (HCV), by its prevalence and high treatment costs, require specific public policies in the Brazilian Unified Health System (SUS). Additionaly, patients infected with HCV and treated with pegylated interferon, conventional interferon and ribavirin develop a number of laboratory test abnormalities and adverse.. The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress.